Skip to Main Content

Paper Details

Multimodal platform for assessing drug distribution and response in clinical trials.
Neuro Oncol
4
2022
-, PDX tumors, Patient, Patient derived xenograft (PDX) lines, Wee-1, adavosertib, glioblastoma, patient, patients, tumors
Author NameAffiliation
Giorgio GagliaBrigham and Women's Hospital, Harvard Medical School
Michael S ReganBrigham and Women's Hospital, Harvard Medical School
Jeffrey N AgarNortheastern University
Soumya RaychaudhuriCenter for Data Sciences, Brigham and Women's Hospital
Soumya RaychaudhuriBroad Institute of MIT and Harvard
Soumya RaychaudhuriHarvard Medical School
Soumya RaychaudhuriBrigham and Women's Hospital and Harvard Medical School
Soumya RaychaudhuriCenter for Data Sciences, Brigham and Women's Hospital
Soumya RaychaudhuriBrigham and Women's Hospital and Harvard Medical School
Soumya RaychaudhuriHarvard Medical School
Soumya RaychaudhuriBroad Institute of MIT and Harvard
Keith L LigonBrigham and Women's Hospital, Harvard Medical School
Patrick Y WenCenter for Neuro-Oncology, Dana-Farber Cancer Institute
Sandro SantagataBrigham and Women's Hospital, Harvard Medical School
Jann N SarkariaMayo Clinic
Forest M WhiteMassachusetts Institute of Technology
Forest M WhiteKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology
Forest M WhiteCenter for Precision Cancer Medicine, Massachusetts Institute of Technology
Nathalie Y R AgarBrigham and Women's Hospital, Harvard Medical School
Nathalie Y R AgarBrigham and Women's Hospital, Harvard Medical School
Nathalie Y R AgarDana-Farber Cancer Institute, Harvard Medical School
  • 1 - 21

Datasets